Unusual 11 Mid-Day Movers 11/7: (NILE) (MFIN) (IONS) Higher; (CXRX) (CHRS) (HLTH) Lower

November 7, 2016 12:53 PM EST

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Concordia International (Nasdaq: CXRX) 35.4% LOWER; reported Q3 EPS of $0.69, $0.35 worse than the analyst estimate of $1.04. Revenue for the quarter came in at $185.5 million versus the consensus estimate of $206 million. Concordia is suspending guidance as the Company assesses the business under new leadership.

Blue Nile (Nasdaq: NILE) 33.4% HIGHER; announced that it has entered into a definitive agreement to be acquired by an Investor Group comprised of funds managed by Bain Capital Private Equity and Bow Street LLC.

Medallion Financial Corp. (Nasdaq: MFIN) 25.2% HIGHER; reported Q316 results. Net investment income was ($0.11) for the quarter and ($0.08) in the nine months, compared to $0.17 and $0.55 in the 2015 periods; however, combined with Medallion Bank, net investment income was $0.67 and $1.57 for the quarter and nine months, compared to $0.42 and $1.12 a year ago.

Ionis Pharmaceuticals (Nasdaq: IONS) 19.2% HIGHER; Biogen and Ionis Pharma announced that SPINRAZA (nusinersen), an investigational treatment for spinal muscular atrophy (SMA), met the primary endpoint at the interim analysis of CHERISH, the Phase 3 study evaluating SPINRAZA in later-onset (consistent with Type 2) SMA. The analysis found that children receiving SPINRAZA experienced a highly statistically significant improvement in motor function compared to those who did not receive treatment. SPINRAZA demonstrated a favorable safety profile in the study.

Amicus Therapeutics (Nasdaq: FOLD) 18.7% HIGHER; reported Q3 EPS of ($0.33), $0.01 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $2.1 million versus the consensus estimate of $1.71 million.

Datalink Corporation (Nasdaq: DTLK) 18.4% HIGHER; Insight Enterprises and Datalink entered into a definitive merger agreement under which Insight will acquire Datalink for $11.25 per share in cash.

Coherus BioSciences, Inc. (Nasdaq: CHRS) 15.8% LOWER; announced that it has received a decision from the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office denying institution of Coherus’ petition for Inter Partes Review (IPR) of AbbVie’s U.S. Patent 9,114,166 (the “’166 Patent”) related to AbbVie’s HUMIRA (adalimumab) formulation.

LendingClub (NYSE: LC) 15.1% HIGHER; reported Q3 EPS of ($0.04), $0.03 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $112.6 million versus the consensus estimate of $103.31 million. Loan originations in the third quarter of 2016 were $1.97 billion, up 1% compared to the $1.96 billion we reported in the second quarter of 2016, but down 12% compared to $2.24 billion in the same quarter last year.

Nobilis Health (NYSE: HLTH) 13.3% LOWER; reported Q3 EPS of ($0.04), $0.11 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $70.7 million versus the consensus estimate of $63.65 million.

BioAmber (NYSE: BIOA) 12.2% LOWER; continuing lower following a Q3 results miss late last weeek.

Chiasma, Inc. (Nasdaq: CHMA) 12.2% LOWER; Chiasma disclosed the following late last Friday: On November 3, 2016, Ansbert Gadicke, M.D. resigned from the Board of Directors (the “Board”) of Chiasma, Inc., effective as of the close of business on November 3, 2016. The decision by Dr. Gadicke was not a result of any disagreement with the Company or the Board.

To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Related Entities

Bain Capital, Unusual 11 Mid-Day Movers, Definitive Agreement

Add Your Comment